SK Biopharmaceuticals Licenses Opacalium in 1 Trillion-Won Deal

SK Biopharmaceuticals President Lee Dong-hoon speaks at a press conference held in Jung-gu, Seoul, on the afternoon of August 26. (Photo provided by SK Biopharmaceuticals) SK Biopharmaceuticals has strengthened its new epilepsy drug pipeline through an in-licensing (L/I) deal worth 1 trillion won (about $722 million). The strategy is to solidify its cash-generating capabilities by focusing on what…